NASDAQ:VERU Veru Q2 2026 Earnings Results & Report $2.46 +0.04 (+1.65%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$2.49 +0.03 (+1.06%) As of 10/9/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Veru beat analyst earnings expectations in its Q2 2026 results, released May 13, 2026. The company reported EPS of -$0.13 versus the -$0.2850 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateMay 13, 2026TimeBefore Market OpensConference Call8:00 AM ET Veru EPS ResultsActual EPS-$0.13Consensus EPS -$0.2850Beat/MissBeat by +$0.1550One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersVeru Revenue ResultsActual RevenueN/AExpected Revenue$1.90 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsVeru's Q4 2026 earnings is estimated for Thursday, November 26, 2026, based on past reporting schedulesConference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileConference Call Audio Live Call not available Earnings Conference CallVeru Q2 202600:00 / 00:00Speed:1x1.25x1.5x2xPowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Veru Q2 2026 Earnings FAQ Did Veru beat earnings estimates for Q2 2026? Veru (NASDAQ:VERU) reported earnings of -$0.13 per share for Q2 2026, beating the consensus estimate of -$0.2850. The report was announced on Wednesday, May 13, 2026. Where can I read Veru's Q2 2026 earnings call transcript? The full Veru Q2 2026 earnings conference call transcript is published on this page, including prepared remarks and the analyst Q&A session, along with the participants who spoke on the call. When is Veru's next earnings date? Veru's next earnings date is estimated for Thursday, November 26, 2026. MarketBeat tracks confirmed and estimated earnings dates for Veru on the company's earnings history page. Veru Earnings HeadlinesVeru (NASDAQ:VERU) Stock Picked Up by Analysts at Westpark CapitalOctober 8 at 2:36 AM | americanbankingnews.comVeru Advances Sabizabulin Toward Phase 2b Trial In Daraxonrasib-Resistant Pancreatic CancerSeptember 8, 2026 | rttnews.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 11 at 1:00 AM | Base Camp Trading (Ad)Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant ...September 8, 2026 | finance.yahoo.comVeru refocuses sabizabulin on post-daraxonrasib oncologySeptember 8, 2026 | tipranks.comVeru Inc. Announces Sabizabulin Overcomes Daraxonrasib Resistance in Preclinical Pancreatic Cancer Studies and Advances Phase 2b Development PlanSeptember 8, 2026 | quiverquant.comQSee More Veru Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Veru? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veru and other key companies, straight to your email. Email Address About VeruVeru (NASDAQ:VERU) is a clinical-stage biopharmaceutical company focused on developing medicines for obesity, oncology and related conditions. The company’s research programs are designed to address cancer-related muscle loss and treatment challenges, as well as the loss of lean muscle that can accompany significant weight reduction. Veru’s lead investigational product, enobosarm, is an oral selective androgen receptor modulator being studied for its potential to preserve or increase muscle mass and improve physical function. The company has evaluated enobosarm in patients with advanced breast cancer and is also studying its potential use in obesity management, including in combination with weight-loss treatments. Veru previously developed sabizabulin, an oral drug candidate investigated for cancer and COVID-19, but the program did not receive regulatory approval for COVID-19. The company was formerly known as Apricus Biosciences and adopted the Veru name in 2018. Veru is headquartered in Miami, Florida, and its operations are primarily focused on global clinical development and regulatory activities rather than a broad commercial product portfolio. Mitchell H. Steiner, M.D., is the company’s founder, chairman and chief executive officer.View Veru ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
